Literature DB >> 2567934

In-vivo anti-CD3 treatment of autoimmune patients.

L Chatenoud, C Ferran, J F Bach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2567934     DOI： 10.1016/s0140-6736(89)90226-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Protection of nonobese diabetic mice from autoimmune diabetes by reduction of islet mass before insulitis.

Authors:  A Itoh; T Maki
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

2.  Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies.

Authors:  T E Feasby
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

3.  In vivo activity and in vitro specificity of CD4+ Th1 and Th2 cells derived from the spleens of diabetic NOD mice.

Authors:  D Healey; P Ozegbe; S Arden; P Chandler; J Hutton; A Cooke
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

4.  Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance.

Authors:  Jason Gaglia; Stephan Kissler
Journal:  Biochemistry       Date:  2019-09-24       Impact factor: 3.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.